Northern Trust Corp Eagle Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 31,955 shares of EGRX stock, worth $19,173. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,955
Previous 94,062 66.03%
Holding current value
$19,173
Previous $526,000 77.57%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$3.71 - $6.07 $230,416 - $376,989
-62,107 Reduced 66.03%
31,955 $118,000
Q2 2024

Aug 14, 2024
SELL
$3.34 - $5.6 $18,169 - $30,463
-5,440 Reduced 5.47%
94,062 $526,000
Q1 2024

May 14, 2024
SELL
$4.26 - $6.51 $27,566 - $42,126
-6,471 Reduced 6.11%
99,502 $521,000
Q4 2023

Feb 13, 2024
BUY
$4.63 - $15.21 $40,401 - $132,722
8,726 Added 8.97%
105,973 $554,000
Q3 2023

Nov 13, 2023
SELL
$15.21 - $22.88 $151,887 - $228,479
-9,986 Reduced 9.31%
97,247 $1.53 Million
Q2 2023

Aug 11, 2023
SELL
$17.74 - $31.87 $239,844 - $430,882
-13,520 Reduced 11.2%
107,233 $2.08 Million
Q1 2023

May 15, 2023
BUY
$25.06 - $34.09 $60,870 - $82,804
2,429 Added 2.05%
120,753 $3.43 Million
Q4 2022

Feb 13, 2023
BUY
$24.98 - $39.77 $58,078 - $92,465
2,325 Added 2.0%
118,324 $3.46 Million
Q3 2022

Nov 14, 2022
SELL
$26.42 - $47.12 $1.24 Million - $2.22 Million
-47,102 Reduced 28.88%
115,999 $3.07 Million
Q2 2022

Aug 12, 2022
BUY
$41.26 - $51.35 $940,480 - $1.17 Million
22,794 Added 16.25%
163,101 $7.25 Million
Q1 2022

May 13, 2022
SELL
$44.58 - $52.6 $166,015 - $195,882
-3,724 Reduced 2.59%
140,307 $6.94 Million
Q4 2021

Feb 08, 2022
SELL
$45.82 - $56.9 $224,105 - $278,297
-4,891 Reduced 3.28%
144,031 $7.33 Million
Q3 2021

Nov 15, 2021
SELL
$43.79 - $55.78 $185,757 - $236,618
-4,242 Reduced 2.77%
148,922 $8.31 Million
Q2 2021

Aug 13, 2021
BUY
$36.86 - $44.5 $700,376 - $845,544
19,001 Added 14.16%
153,164 $6.56 Million
Q1 2021

May 12, 2021
SELL
$40.32 - $50.97 $128,782 - $162,798
-3,194 Reduced 2.33%
134,163 $5.6 Million
Q4 2020

Feb 11, 2021
SELL
$41.72 - $51.34 $367,678 - $452,459
-8,813 Reduced 6.03%
137,357 $6.4 Million
Q3 2020

Nov 16, 2020
SELL
$37.02 - $51.28 $209,570 - $290,296
-5,661 Reduced 3.73%
146,170 $6.21 Million
Q2 2020

Aug 14, 2020
BUY
$43.24 - $55.02 $721,502 - $918,063
16,686 Added 12.35%
151,831 $7.29 Million
Q1 2020

May 14, 2020
BUY
$34.37 - $60.07 $56,366 - $98,514
1,640 Added 1.23%
135,145 $6.22 Million
Q4 2019

Feb 14, 2020
SELL
$54.32 - $64.31 $201,581 - $238,654
-3,711 Reduced 2.7%
133,505 $8.02 Million
Q3 2019

Nov 13, 2019
SELL
$53.25 - $59.98 $446,288 - $502,692
-8,381 Reduced 5.76%
137,216 $7.76 Million
Q2 2019

Aug 13, 2019
BUY
$46.61 - $58.45 $24,656 - $30,920
529 Added 0.36%
145,597 $8.11 Million
Q1 2019

May 13, 2019
SELL
$38.66 - $51.82 $28,492 - $38,191
-737 Reduced 0.51%
145,068 $7.32 Million
Q4 2018

Feb 12, 2019
SELL
$36.72 - $67.73 $1.32 Million - $2.44 Million
-35,975 Reduced 19.79%
145,805 $5.88 Million
Q3 2018

Nov 14, 2018
BUY
$66.65 - $83.86 $1.15 Million - $1.44 Million
17,209 Added 10.46%
181,780 $12.6 Million
Q2 2018

Sep 18, 2018
SELL
$51.25 - $76.62 $50,378 - $75,317
-983 Reduced 0.59%
164,571 $12.5 Million
Q2 2018

Aug 14, 2018
BUY
$51.25 - $76.62 $1.63 Million - $2.43 Million
31,756 Added 23.73%
165,554 $12.5 Million
Q1 2018

May 09, 2018
BUY
$52.16 - $66.86 $286,619 - $367,395
5,495 Added 4.28%
133,798 $7.05 Million
Q4 2017

Feb 14, 2018
SELL
$49.6 - $60.87 $217,347 - $266,732
-4,382 Reduced 3.3%
128,303 $6.85 Million
Q3 2017

Nov 13, 2017
BUY
$46.62 - $60.36 $6.19 Million - $8.01 Million
132,685
132,685 $7.91 Million

Others Institutions Holding EGRX

# of Institutions
70
Shares Held
8.6M
Call Options Held
1M
Put Options Held
100
View Full List

About EAGLE PHARMACEUTICALS, INC.

EGRX Quotes by TradingView
  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $7.81M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email